Atrial Fibrillation (AF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Atrial fibrillation (AF) is the most typical sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke. AF causes an estimated 15% of all strokes, and it accounts for one-third of strokes in individuals aged 65 years or older. AF is a complex disease with only a partly elucidated pathophysiology; it is the subject of extensive medical research, believing that a complete understanding of AF will yield novel drug therapies with improved effectiveness and safety profiles over current drugs. In keeping with other forms of cardiac arrhythmia, both a triggering factor and a substrate are thought to be required for AF induction; early-stage research has identified several novel targets that have the potential to prevent abnormal impulse formation (the trigger) and help reverse long-term structural and electrical remodeling. Guidelines prepared by the American Heart Association (AHA)/The American College of Cardiology (ACC)/European Society of Cardiology (ESC) classify AF into four major categories. Atrial fibrillation (AF) is classified based on its duration and reversibility into sinus rhythm. The last three categories apply to recurrent AF episodes. The first-detected episode of AF can be symptomatic or self-limiting, and the diagnosing physician may be uncertain about the episode’s duration and previous episodes.
• Atrial fibrillation (AF) prevalence increased from 0.1% among adults younger than 55 years to 8.5% in 80 years or older persons. Approximately 2.12 MN to 2.4 MN US adults are currently diagnosed with AF.

Thelansis’s “Atrial Fibrillation (AF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrial Fibrillation (AF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Atrial Fibrillation (AF) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Atrial Fibrillation (AF) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Atrial Fibrillation (AF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Atrial Fibrillation (AF), Atrial Fibrillation (AF) market outlook, Atrial Fibrillation (AF) competitive landscape, Atrial Fibrillation (AF) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)